STTK

Shattuck Labs, Inc. (STTK) - 2024 Annual Report Summary

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2024. Shattuck Labs, Inc. is a preclinical-stage biotechnology company focused on developing treatments for inflammatory and immune-mediated diseases, specifically Inflammatory Bowel Disease (IBD). The company's lead program is SL-325, a first-in-class Death Receptor 3 (DR3) antagonist antibody. The company is classified as an Emerging Growth Company and a Smaller Reporting Company.

Key Financial Metrics

Note: The company has no debt and no products approved for commercial sale. Revenue is derived solely from collaboration agreements.

Material Changes vs. Prior Period

• Revenue Increase: Collaboration revenue increased 245% to $5.7 million, driven by the recognition of $3.4 million in research activities and a $2.0 million option fee from the terminated Ono Pharmaceutical agreement, partially offset by a decrease in ImmunoGen revenue.
• Expense Reduction: R&D expenses decreased 9.6% to $67.2 million. This reduction was primarily due to the discontinuation of the SL-172154 clinical program, resulting in lower manufacturing costs, reduced lab material consumption, and headcount reductions.
• Program Discontinuation: In October 2024, the company discontinued the clinical development of SL-172154 following overall survival data readouts. This triggered a restructuring plan impacting approximately 40% of the workforce and incurring $1.0 million in one-time termination benefits.
• Liquidity Position: Cash and investments decreased by approximately $57.6 million year-over-year, reflecting the net cash burn from operations and investing activities (net purchase of government securities).

Guidance, Outlook, and Risks

• Development Timeline: The company expects to file an Investigational New Drug (IND) application for SL-325 in the third quarter of 2025. Enrollment for the Phase 1 clinical trial is expected to be completed in the second quarter of 2026.
• Capital Runway: Management estimates that existing cash, cash equivalents, and investments ($73.0 million as of Dec 31, 2024) are sufficient to fund projected operations into 2027.
• Strategic Focus: The company has pivoted to focus exclusively on the DR3 program (SL-325 and related bispecifics) following the termination of the Ono collaboration and discontinuation of SL-172154.
• Key Risks:
  • Preclinical Stage: SL-325 has not yet been tested in humans; there is no guarantee of safety or efficacy.
  • Funding Needs: The company will require additional capital to complete development and commercialization. Failure to raise funds could force delays or program termination.
  • Third-Party Dependence: The company relies on third-party contract manufacturers (Kemwell Biopharma) and CROs for all manufacturing and clinical trial execution.
  • Regulatory Uncertainty: Potential disruptions at the FDA due to government staffing changes or policy shifts could delay regulatory submissions.

Investor Verification Checklist

• Cash Runway Validation: Verify the $73.0 million cash balance and the assumption that it funds operations into 2027, considering potential inflation or cost overruns.
• SL-325 Preclinical Data: Review the specific non-human primate (NHP) toxicology data and receptor occupancy (RO) metrics to assess the de-risking of the Phase 1 trial.
• Manufacturing Capacity: Confirm the status of the cGMP manufacturing process transfer to Kemwell Biopharma and the timeline for producing clinical trial material.
• Collaboration Revenue Sustainability: Note that all revenue-generating collaboration agreements (Ono and ImmunoGen) have been completed or terminated; future revenue is not expected until new partnerships are formed.
• Restructuring Costs: Confirm that the $1.0 million restructuring charge related to the SL-172154 discontinuation has been fully accounted for and that no further significant one-time costs are anticipated.